(2,3-二氢-5-甲基-3-((4-吗啉基)甲基)吡咯并-(1,2,3-de)-1,4-苯并恶嗪-6-基)(1-萘基)甲酮单甲烷磺酸盐 | 131543-22-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: (2,3-二氢-5-甲基-3-((4-吗啉基)甲基)吡咯并-(1,2,3-de)-1,4-苯并恶嗪-6-基)(1-萘基)甲酮单甲烷磺酸盐
• 英文名称: WIN 55,212-2
• 英文别名: (+)-Win 55212-2；((R)‐(+)‐(2,3‐dihydro‐5‐methyl‐3‐(4‐morpholinylmethyl)pyrrolo(1,2,3‐de)‐1,4‐benzoxazin‐6‐yl)‐1‐naphthalenylmethanone)；(R)‐(+)‐[2,3‐dihydro‐5‐methyl‐3‐(4‐morpholinylmethyl)pyrrolo[1,2,3‐de]‐1,4‐benzoxazin‐6‐yl]‐1‐naphthalenylmethanone；[(3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone monomethanesulfonate；(11R)-2-methyl-11-[(morpholin-4-yl)methyl]-3-(naphthalene-1-carbonyl)-9-oxa-1-azatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraene；(R)-(1)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate；(2,3-Dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl)methanone monomethanesulfonate；[(11R)-2-methyl-11-(morpholin-4-ylmethyl)-9-oxa-1-azatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraen-3-yl]-naphthalen-1-ylmethanone
• CAS: 131543-22-1
• 化学式: C₂₇H₂₆N₂O₃
• 分子量: 426.515
• InChiKey: HQVHOQAKMCMIIM-HXUWFJFHSA-N

物化性质

• 沸点：
  627.7±55.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  43.7
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  在 lithium aluminium tetrahydride 、 溶剂黄146 、 3-硝基苯磺酸吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 生成 (2,3-二氢-5-甲基-3-((4-吗啉基)甲基)吡咯并-(1,2,3-de)-1,4-苯并恶嗪-6-基)(1-萘基)甲酮单甲烷磺酸盐
  参考文献：
  名称：

  pravadoline的构象受限类似物：大麻素受体的纳摩尔强效，对映选择性，（氨基烷基）吲哚激动剂。

  摘要：

  Pravadoline（1）是一种（氨基烷基）吲哚镇痛药，它是环氧合酶的抑制剂，与其他NSAID相比，抑制小鼠输精管（MVD）制剂中神经刺激的收缩（IC50 = 0.45 microM）。合成了许多pravadoline的受构象限制的杂环类似物，其中吗啉代乙基侧链束缚在吲哚核上。抑制吗啉会降低这些pravadoline类似物在体外抑制前列腺素合成的能力。相反，在[2,3-二氢-5-甲基-3-[（4-吗啉基）甲基]吡咯并[1,2,3-de] -1,4-苯并恶嗪-6中增强了小鼠输精管的抑制活性。 -基]-（4-甲氧基苯基）亚甲基（20）。仅20的R对映体具有活性（IC 50 ＝0.044μM）。在研究的类似物中，吗啉氮对于MVD抑制活性的最佳方向是在右下象限，在吲哚环定义的平面下方。（20）和最有效的类似物（R）-（+）-[2,3-二氢-5-甲基-3-[（4-吗啉基）甲基]吡咯[1,2，制备3-de]

  DOI：

  10.1021/jm00079a016

文献信息

• Multitarget Compounds Active at a PPAR and Cannabinoid Receptor
  申请人：Desreumaux Pierre

  公开号：US20110039808A1

  公开（公告）日：2011-02-17

  There is a need for pharmaceutical compounds which have activity at, at least one of a PPAR and a cannabinoid receptor. Thus there are provided such compounds, wherein the compound comprises: a PPAR pharmacophore and a cannabinoid pharmacophore linked together by a moiety comprising a fused bicyclic ring comprising a five membered ring fused with a six membered ring or a six membered ring fused with a six membered ring; wherein the cannabinoid pharmacophore comprises the fused bicyclic ring; and the PPAR pharmacophore comprises a salicylic acid, alkoxybenzylacetic acid or a alkoxyphenylacetic acid functionality; and wherein the PPAR pharmacophore is linked to the bicyclic ring of the cannabinoid pharmacophore through a linker comprising an amine or an amide functional group.

  需要具有至少一种PPAR和大麻受体活性的药物化合物。因此提供了这样的化合物，其中该化合物包括：由包含一个五元环与一个六元环或一个六元环与一个六元环融合的融合双环环的基团连接在一起的PPAR药效团和大麻药效团；其中大麻药效团包括融合双环环；而PPAR药效团包括水杨酸、烷氧基苯乙酸或烷氧基苯乙酸官能团；PPAR药效团通过包含胺基或酰胺官能团的连接物连接到大麻药效团的双环环上。
• [EN] NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION<br/>[FR] NOUVEAUX LIGANDS DU RÉCEPTEUR CANNOBINOÏDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR PROCÉDÉ DE PRÉPARATION
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2009053799A1

  公开（公告）日：2009-04-30

  The present invention relates to compounds of f formula (I) as cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2 ) receptor modulators, and uses thereof f or treating diseases, conditions and/or disorders modulated by a cannabinoid receptor ( such as pain, neurodegenrative disorders, eating disorders, weight loss or control, and obesity).

  本发明涉及公式（I）的化合物作为大麻素受体调节剂，特别是大麻素1（CB1）或大麻素2（CB2）受体调节剂，以及它们的用途用于治疗由大麻素受体调节的疾病、症状和/或障碍（如疼痛、神经退行性疾病、进食障碍、体重减轻或控制以及肥胖症）。
• PAINKILLING ASSOCIATION COMPRISING A DIHYDROIMIDAZOPYRAZINE DERIVATIVE
  申请人：Auguet Michel

  公开号：US20090270400A1

  公开（公告）日：2009-10-29

  The invention relates to a product comprising (1R)-1-[((2R)-2-amino-3-[(8S)-8-(cyclohexylmethyl) -2-phenyl-5,6-dihydroimidazo [1,2-a]pyrazin-7(8H)-yl]-3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl) -2-phenyl-5,6-dihydrolmidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine in association with an analgesic agent selected from morphine, the similar or a morphine derivative, sodium channel inhibitors, non-steroidal antiflammatory agents (AINS), glutamatergic system inhibitors, tricycle antidepressants and gabaergic derivatives for simultaneous therapeutic use which is separated or out over the time for pain treatment or prevention.

  该发明涉及一种产品，其中包含(1R)-1-[((2R)-2-氨基-3-[(8S)-8-(环己甲基)-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7(8H)-基]-3-氧代丙基}二硫)甲基]-2-[(8S)-8-(环己甲基)-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7(8H)-基]-2-氧代乙胺，与吗啡、类似物或吗啡衍生物、钠通道抑制剂、非甾体抗炎药（AINS）、谷氨酸系统抑制剂、三环抗抑郁药和GABA能衍生物中选择的镇痛药联合使用，用于同时治疗或预防疼痛的分隔或延时。
• NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION
  申请人：Muthuppalaniappan Meyyappan

  公开号：US20080200501A1

  公开（公告）日：2008-08-21

  The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).

  本发明涉及新型大麻素受体调节剂，特别是大麻素1（CB1）或大麻素2（CB2）受体调节剂，以及它们用于治疗受大麻素受体调节的疾病、症状和/或紊乱（如疼痛、神经退行性疾病、进食紊乱、体重减轻或控制以及肥胖）的用途。
• PREPARATION AND UTILITY OF SUBSTITUTED PYRAZOLE COMPOUNDS WITH CANNABINOID RECEPTOR ACTIVITY
  申请人：GANT G. Thomas

  公开号：US20070287734A1

  公开（公告）日：2007-12-13

  The present disclosure is directed to modulators of CB-1 type receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of the severity and duration of obesity, metabolic syndrome, dyslipidemia, glucose imbalance, the inability to maintain weight loss, insulin resistance, a cardiovascular disorder, memory loss, drug dependence, a depressive disorder, a panic disorder, an obsessive-compulsive disorder, anxiety, post-traumatic stress syndrome, and any other condition in which it is beneficial to inhibit, inversely agonize or modulate a cannabinoid receptor are described.

  本披露涉及CB-1型受体的调节剂及其药用盐和前药，其化学合成，以及这些化合物的医学用途，用于治疗和/或管理肥胖、代谢综合征、血脂异常、葡萄糖失衡、无法维持体重减轻、胰岛素抵抗、心血管疾病、记忆丧失、药物依赖、抑郁症、恐慌症、强迫症、焦虑、创伤后应激综合征以及其他有益于抑制、反向激动或调节大麻素受体的情况。